Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HUA MEDICINE
華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2552)

PROPOSED ADOPTION OF THE FOURTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

The board of directors (the "**Board**") of Hua Medicine (the "**Company**") proposes to amend certain provisions of its third amended and restated memorandum and articles of association of the Company (the "**existing Articles**") by way of adoption of the fourth amended and restated memorandum and articles of association (the "**amended Articles**") to (i) allow the Company's general meeting to be held in the form of an electronic meeting or a hybrid meeting and provide for voting by electronic means; and (ii) make other consequential and housekeeping amendments.

The adoption of the amended Articles is subject to the approval of the shareholders of the Company (the "**Shareholders**") by way of a special resolution at the annual general meeting of the Company (the "**AGM**") and if approved by the Shareholders, will become effective upon the approval by the Shareholders at the AGM.

A circular containing, among other matters, details of the proposed adoption of the amended Articles, together with a notice of the AGM will be despatched to the Shareholders in due course.

By Order of the Board
Dr. Li Chen
Chief Executive Officer and Executive Director

Hong Kong, April 16, 2026

As at the date of this announcement, the Board of Directors comprises Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang as executive Directors; Mr. Robert Taylor Nelsen as non-executive Director; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.